Developing a cream to relieve pain from burns by blocking specific pain receptors.
Topical treatment for burn pain by blocking cutaneous pain receptors.
This study is testing a new cream that could help relieve burn pain by targeting specific pain receptors in the skin, and it's designed for anyone suffering from burns who wants a treatment with fewer side effects than traditional pain medications.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Serentrix, LLC NIH-funded |
| Lab location | 1 site (Exton, United States) |
| Project ID | NIH-10821060 on NIH RePORTER |
What this research studies
This research aims to create a topical treatment for burn pain by targeting the TRPV1 pain receptors in the skin. The approach involves applying a small molecule antagonist directly to the affected area, which has shown promise in animal models for reducing pain and inflammation. By focusing on a localized treatment, the researchers hope to minimize side effects associated with systemic pain medications. The lead compound, SER114, has already been tested in early clinical trials for other types of pain, indicating its potential effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from burn injuries who experience significant pain.
Not a fit: Patients with burn injuries who do not experience pain or those with other underlying conditions that complicate pain management may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective way to manage pain for burn victims, improving their recovery experience.
How similar studies have performed: Previous research has shown success with similar approaches targeting TRPV1 receptors for pain management, indicating a promising avenue for this treatment.
Where this research is happening
Exton, United States
- Serentrix, LLC — Exton, United States (Active)
Researchers
- Principal investigator: Bhargava, Kumaril — Serentrix, LLC
- Study coordinator: Bhargava, Kumaril
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.